Florida Cerebrovascular Disease Biorepository and Genomics Center

Recruiting

• Conditions: Cerebrovascular Disease; Aneurysmal Subarachnoid Hemorrhage; Carotid Artery Stenosis Symptomatic; Asymptomatic Carotid Artery Stenosis; Non-Aneurysmal Perimesencephalic Subarachnoid Haemorrhage; Cerebral Venous Thrombosis; Moyamoya Disease; Reversible Cerebral Vasoconstriction Syndrome; Intracerebral Hemorrhage; Vascular Dementia

• Registration Number: NCT05491980
• Lead Sponsor: Mayo Clinic

Brief Summary

The purpose of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida, which will include collecting medical history information and blood from subjects affected by cerebrovascular disease. The information and blood samples collected may be used in future research for the study of cerebrovascular disease and to learn about, prevent or treat other health problems.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2022-08-02
• Study First Submitted: 2022-08-05
• Study First Submitted QC: 2022-08-05
• Study First Posted: 2022-08-08
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-15
• Last Update Posted: 2024-11-18
• Primary Completion: 2025-08
• Study Completion: 2025-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

• Affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid hemorrhage, leukoaraiosis, arteriovenous fistula, reversible cerebral vasoconstriction syndrome (RCVS), and CADASIL.

Read More

Exclusion Criteria

• All patients with the following known or suspected virulent microorganisms causing an active or latent infection will be excluded from the study:

• Human immunodeficiency virus (HIV);
• Any viral hepatitis;
• West Nile virus (WNV);
• Influenza virus;
• Tuberculosis (TB);
• Any bacteremia;
• Any fungemia;
• Any prionopathy.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Stroke or TIA at 12 months	1 year	Number of participants to experience new diagnosis of TIA or stroke.

Secondary Outcome Measures

Name	Time	Method
Modified Rankin Scale	1 year	Measure of overall functional status

Trial Locations

Locations (1)

Mayo Clinic Florida; 🇺🇸 Jacksonville, Florida, United States